Revolution Medicines(US:RVMD) Globenewswire·2025-02-24 21:05Company Overview - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers [2] - The company's R&D pipeline includes RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins [2] Product Pipeline - Key RAS(ON) inhibitors in clinical development include: - Daraxonrasib (RMC-6236), a multi-selective inhibitor - Elironrasib (RMC-6291), a G12C-selective inhibitor - Zoldonrasib (RMC-9805), a G12D-selective inhibitor [2] - Additional development opportunities focus on RAS(ON) mutant-selective inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [2] Investor Engagement - The CEO Mark A. Goldsmith will participate in three upcoming investor conferences: - TD Cowen 45 Annual Healthcare Conference on March 3 at 1:50 p.m. ET - Barclays 27 Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET - 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET [3]